Seres Therapeutics Inc [NASDAQ: MCRB] stock went on a downward path that fall over -4.88% on Wednesday, amounting to a one-week price decrease of less than -3.51%. The company report on March 28, 2024 at 7:00 AM that Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 700,000 shares of its common stock to Marella Thorell, the Company’s new Executive Vice President and Chief Financial Officer, consisting entirely of stock options.
These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”).
Over the last 12 months, MCRB stock dropped by -87.20%. The one-year Seres Therapeutics Inc stock forecast points to a potential upside of 89.89. The average equity rating for MCRB stock is currently 1.86, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $109.57 million, with 135.04 million shares outstanding and 114.13 million shares in the current float. Compared to the average trading volume of 4.65M shares, MCRB stock reached a trading volume of 6071827 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Seres Therapeutics Inc [MCRB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MCRB shares is $7.22 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MCRB stock is a recommendation set at 1.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Seres Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 26, 2023. While these analysts kept the previous recommendation, JP Morgan raised their target price to Neutral. The new note on the price target was released on April 21, 2023, representing the official price target for Seres Therapeutics Inc stock. Previously, the target price had yet another drop from $24 to $7, while Goldman kept a Sell rating on MCRB stock.
The Average True Range (ATR) for Seres Therapeutics Inc is set at 0.07, with the Price to Sales ratio for MCRB stock in the period of the last 12 months amounting to 0.87.
MCRB Stock Performance Analysis:
Seres Therapeutics Inc [MCRB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.51. With this latest performance, MCRB shares dropped by -36.35% in over the last four-week period, additionally sinking by -66.25% over the last 6 months – not to mention a drop of -87.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MCRB stock in for the last two-week period is set at 33.16, with the RSI for the last a single of trading hit 30.27, and the three-weeks RSI is set at 35.82 for Seres Therapeutics Inc [MCRB]. The present Moving Average for the last 50 days of trading for this stock 0.9938, while it was recorded at 0.7619 for the last single week of trading, and 2.2165 for the last 200 days.
Insight into Seres Therapeutics Inc Fundamentals:
Seres Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.48 and a Current Ratio set at 1.78.
MCRB Stock EPS
With the latest financial reports released by the company, Seres Therapeutics Inc posted -0.57/share EPS, while the average EPS was predicted by analysts to be reported at -0.55/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -3.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MCRB.
Seres Therapeutics Inc [MCRB] Institutonal Ownership Details
The top three institutional holders of MCRB stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in MCRB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in MCRB stock with ownership which is approximately 5.8386%.
